Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Research & Development (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Research & Development for 10 consecutive years, with $1.0 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 91.52% to $1.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $36.7 million through Dec 2025, down 2.5% year-over-year, with the annual reading at $62.4 million for FY2025, 65.62% up from the prior year.
  • Research & Development for Q4 2025 was $1.0 million at Akebia Therapeutics, down from $14.9 million in the prior quarter.
  • The five-year high for Research & Development was $43.8 million in Q1 2022, with the low at $1.0 million in Q4 2025.
  • Average Research & Development over 5 years is $19.1 million, with a median of $14.1 million recorded in 2023.
  • The sharpest move saw Research & Development tumbled 94.32% in 2021, then skyrocketed 767.57% in 2022.
  • Over 5 years, Research & Development stood at $29.6 million in 2021, then grew by 8.6% to $32.1 million in 2022, then plummeted by 69.27% to $9.9 million in 2023, then increased by 19.47% to $11.8 million in 2024, then plummeted by 91.52% to $1.0 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $1.0 million, $14.9 million, and $11.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.